《HIV免疫逃逸趋向性的改变》

  • 来源专题:艾滋病防治
  • 编译者: 李越
  • 发布时间:2005-04-17
  • The V3 loop of human immunodeficiency virus type 1 is both a determinant of viral cell tropism and a target for neutralizing antibodies. This relationship was investigated. Selection of a dual-tropic (T cells and macrophages) virus to replicate in CD4+ brain cells results in loss of macrophage tropism and of neutralization by an anti-V3 loop monoclonal antibody. Moreover, selection of the brain-selected variant to escape from V3 loop-specific neutralizing monoclonal antibodies results in the reduction or loss of brain cell tropism and the reacquisition of macrophage tropism. These data may indicate that the antigenic diversification of human immunodeficiency virus type 1 apparent after seroconversion can be selected either by immune responses or by colonization of new cell types.
  • 原文来源:http://www.pubmedcentral.gov/picrender.fcgi?artid=189019&blobtype=pdf
相关报告
  • 《抗原加工改变的免疫选择导致慢性HIV-1感染的CTL逃逸》

    • 来源专题:艾滋病防治
    • 编译者:李越
    • 发布时间:2005-04-15
    • Mutations within cytotoxic T lymphocyte (CTL) epitopes impair T cell recognition, but escape mutations arising in flanking regions that alter antigen processing have not been defined in natural human infections. In human histocompatibility leukocyte antigen (HLA)-B57+ HIV-infected persons, immune selection pressure leads to a mutation from alanine to proline at Gag residue 146 immediately preceding the NH2 terminus of a dominant HLA-B57–restricted epitope, ISPRTLNAW. Although N-extended wild-type or mutant peptides remained well-recognized, mutant virus–infected CD4 T cells failed to be recognized by the same CTL clones. The A146P mutation prevented NH2-terminal trimming of the optimal epitope by the endoplasmic reticulum aminopeptidase I. These results demonstrate that allele-associated sequence variation within the flanking region of CTL epitopes can alter antigen processing. Identifying such mutations is of major relevance in the construction of vaccine sequences.
  • 《结直肠癌的免疫治疗和免疫逃逸》

    • 来源专题:生物医药
    • 编译者:杜慧
    • 发布时间:2023-07-17
    • 免疫疗法在临床试验中的巨大成功使其成为癌症治疗的一个新支柱。然而,在微卫星稳定型结直肠癌(MSS-CRC)中,几乎没有取得临床疗效。本篇文章讨论了CRC的分子和遗传异质性。研究人员回顾了免疫逃逸机制,并重点介绍了免疫疗法作为CRC治疗方式的最新进展。通过更好地了解肿瘤微环境(TME)和免疫逃逸的分子机制,本综述为制定对CRC各亚群患者有效的治疗策略提供了启示。